Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 10Genitourinary 5Sarcoma 4Other solid neoplasm 3Head & Neck 2Dermatologic 2CNS 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1Endocrine 1

Conditions

Solid Tumors 2Solid Tumor 1

Interventions

Cisplatin 145pembrolizumab 129Carboplatin 125Injections 108Pemetrexed 97Paclitaxel 97Gemcitabine 85Irinotecan 75Nivolumab 71Cyclophosphamide 71Docetaxel 68Bevacizumab 57Oxaliplatin 49Fluorouracil 48atezolizumab 46Capecitabine 46Etoposide 42Leucovorin 41tislelizumab 40toripalimab 36fludarabine 32Ipilimumab 30Drug Therapy 30Topotecan 29durvalumab 28Vincristine 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26Specimen Handling 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × TH 302 × Other solid neoplasm × Clear all
NCT01485042 2017-09-01

PATH

Duke University

Phase 1 Completed
50 enrolled
Other solid neoplasm

Solid Tumors

NCT02076230 2016-06-10

A Phase 1 TH-302 Mass Balance Trial

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
10 enrolled
Other solid neoplasm

Solid Tumor

NCT02020226 2016-06-02

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1 Unknown
40 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡